Spring conjunctivitis is an eye allergy, more common during this time of year. Allergens such as tree or grass pollen, which are more present in spring, worsen its symptoms.
Pathologies and Treatments
Symptoms
Spring conjunctivitis is an eye disease mainly caused by ocular allergy. Itching is the main symptom of this disease. In addition, there is usually red eye, tearing, eyelid inflammation, discharge, eye pain and, in severe cases, photophobia and blurred vision.
Sometimes, spring conjunctivitis is associated with nasal involvement, such as allergic rhinitis, or pharyngeal involvement, since ocular allergy is often combined with other respiratory allergies.
Prevention
Environmental control is the basic care for people with spring conjunctivitis. It is important to identify the agent that caused the spring conjunctivitis and avoid contact with it. When exposure has already occurred, washing the affected eye with sterile saline solution or artificial tears helps clean allergens from the ocular surface and reduce the contact time.
Allergy tests should be performed to determine the allergens that caused the ocular allergy. In this way, a possible treatment with vaccines can be considered.
Procedures
Medicina regenerativa: Endoret
Con el tratamiento de medicina regenerativa Endoret propiciamos la reparación de la superficie ocular afectada por la sequedad ocular. Se trata de un plasma rico en factores de crecimiento para el tratamiento de las lesiones de la superficie ocular elaborado a partir de la sangre del mismo paciente. Con esta formulación individualizada se consigue una tolerancia completa y una efectividad óptima. Esta opción terapéutica revolucionaria es muy eficaz en casos de defectos epiteliales persistentes o úlceras corneales. Asimismo se puede aplicar después de una cirugía refractiva corneal, una cirugía ocular o en el Síndrome de Sjögren.
Dra. Paula Verdaguer,
MD, PhD
Número de Col·legiat COMB: 40737
Ophthalmologist. Specialist in Cornea, Refractive Surgery, and Cataracts
If you found this interesting, feel free to share it here:
Last modified: 19/08/2025